Trial Information
Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study
Inclusion Criteria:
- Histologic diagnosis of NHL:Any histology
- Stage I-IV
- Measurable disease by CT scan (gross disease measuring at least 2 cm in any one
dimension)
- Planned radiation dose prescription >=30 gy, >=20 fractions, >=3weeks duration
- Informed consent
- Previous chemotherapy is allowed, provided the above eligibility criteria are me
Exclusion Criteria:
- To minimize effect from breathing motion, patients presenting with parenchymal lung
tumours and tumours involving liver and stomach will be excluded
- Concurrent systemic chemotherapy (glucocorticoids when used alone is allowed)
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To quantify spatial and temporal treatment response to radiation therapy in patients with NHL using the co-registered CT and FDG-PET images and assess this response with temporal geometric models.
Principal Investigator
Richard Tsang, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Princess Margaret Hospital, Canada
Authority:
Canada: Ethics Review Committee
Study ID:
UHN REB 05-0339-C
NCT ID:
NCT00188929
Start Date:
August 2005
Completion Date:
July 2009
Related Keywords:
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Non-Hodgkin